- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Ad Stars: BBDO (Cypher)
DEVICE DTC
agency: BBDO
brand: Cypher
client: Cordis, a Johnson & Johnson company Agency team names withheld at client's request
A drug-eluding stent isn't something that's typically considered "patient's choice," so it seems counterintuitive to create consumer print ads to promote them. But to the surprise of industry watchers, that's just what BBDO did. Check out the agency's eye-catching campaign for Johnson & Johnson's Cypher stent, launched as full-page spreads in magazines and newspapers beginning in October 2007.
The spots feature people engaging in everyday physical activities, from jogging to playing with children. They also show the actual size of a stent and offer risk-and-benefit information. We like these ads because they educate consumers in an area where most say they don't need to be educated—and that's just nonsense. "It's up to the doctor to determine what's best for the patient, but we wanted to make sure the information was out there," said Cordis' Carol Goodrich, director of corporate communications. "It really is all about physician and patient interaction and conversation about coronary-artery disease."
PREVIOUS AGENCY ‹‹ HOME ›› NEXT AGENCY
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
